8 19

Cited 0 times in

난치성 정신분열증 환자에 대한 Clozapine 치료의 비용 효과

Other Titles
 Cost-Effectiveness of Clozapine Treatment for Patients with Refractory Schizophrenia 
Authors
 이홍식  ;  서호석  ;  김찬형  ;  송동호  ;  김진학 
Citation
 Korean Journal of Psychopharmacology (대한정신약물학회지), Vol.9(1) : 27-34, 1998 
Journal Title
 Korean Journal of Psychopharmacology (대한정신약물학회지) 
ISSN
 1017-5717 
Issue Date
1998
Abstract
Objective:Although antipsychotic treatments are effective for schizophrenia, at least 25% of schizophrenic patients have little response to conventional neuroleptics. Although patients respond well to anti-psychotics initially, they often result in heavy loss of costs and social burden due to the frequent relapse which often require intensive institutional care while the patients experience significant social and functional disabilities. Many studies have come out recently concerning the cost of schizophrenia and its cost-effectiveness in treatment. Clozapine has the risk of agranulocytosis and greater initial cost, however, it has been reported to be cost-effective for the treatment of refractory schizophrenia because of its highly effectiveness, in addition, it has reduced rehospitalization rates and hospital stays. The purpose of this retrospective study was to ascertain the cost-effectiveness of clozapine treatment for patients with refractory schizophrenia in Korea. Method:We studied 17 patients with refractory schizophrenia treated by clozapine over a two year period. The numbers of hospitalization, hospital stays two years before clozapine treatment, and two years after clozapine treatment were investigated. Direct costs of psychiatric hospitalization, outpatient treatment, and other costs were estimated. Data on patients’ clinical characteristics, use of mental health services and information about the cost of treatments were collected from psychiatric hospitalization records, outpatient records and hospital administration records. Some of the patient data information before the introduction of clozapine treatment were gathered through direct interviews of their families. Therapeutic outcome measures included the Clinical Global Impression (CGI) scale and Global Assessment of Functioning (GAF) score. Result:At the initial clozapine treatment, the mean age of subjects was 29 (±7.9) years old. The mean duration of previous psychiatric treatment was 8 (±3.0) years. Average total direct costs were reduced from ₩4,106,480 in the second pretreatment year to ₩2,338,427 in the second posttreatment year while the mean hospitalization costs, a percentage of total direct costs, were reduced from 82.9% to 27.4%. Also, the mean hospital stays per year were decreased from 83.4 days to 15.7 days, the mean numbers of hospitalization from 0.59 to 0.18. CGI scale scores and GAF scores showed a statistically significant clinical improvement between before and after clozapine treatment. Conclusion:These results suggest that a long-term treatment of clozapine for patients with refractory schizophrenia is indeed more cost-effective than conventional neuroleptic treatment. We suggest more comprehensive and prospective study due to the limitations of this retrospective study.
Files in This Item:
T199801169.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Psychiatry (정신과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Chan Hyung(김찬형)
Lee, Hong Shick(이홍식)
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/176371
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links